Elderly heart failure (HF) patients are assumed to prefer improved quality of life over longevity, but sufficient data are lacking. Therefore, we assessed the willingness to trade survival time for quality-of-life (QoL) and the preferences for resuscitation.
the number of CHF-related hospitalizations. 2 Although negative effects may be reduced by combining ICD with cardiac resynchronization in selected patients, 3 the question arises if pure reduction in mortality is the primary goal in all CHF patients or if patients would prefer symptom relief to survival. This question is especially relevant since the average CHF patient is of advanced age with multiple co-morbidities. 4 Intuitively, it may be assumed that particularly elderly patients with severe symptomatic chronic disease would prefer a better QoL to prolonged survival. A significant proportion of younger patients were willing to trade survival time for perfect health. 5, 6 Still, the assumption that older patients are more willing to trade survival time for QoL might be wrong, as sicker patients can express stronger preferences for life-prolonging treatments compared with healthier people. 7 Data giving insight into end-of-life preferences in elderly CHF patients, however, are lacking. Therefore, we aimed to investigate end-of-life and cardiopulmonary resuscitation (CPR) preferences in elderly CHF patients. In addition, predictive factors for willingness to trade survival time for better QoL and for wanting resuscitation if necessary were evaluated.
Methods

Setting and participants
Patients participating in the Trial of Intensified vs. standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF; n ¼ 622) were included in the analysis as described previously. 4, 8 In short, TIME-CHF was a prospective randomized controlled multicentre trial addressing the management of elderly patients with CHF comparing a standard symptom-guided therapy with an intensified, N-terminalpro-B-type natriuretic peptide (NT-BNP) guided medical therapy.
Patients aged ≥60 years, with symptomatic CHF (NYHA ≥II), a history of CHF hospitalization within the last year, and a NT-BNP level .2× the upper limit of normal were included and stratified into two age groups, i.e. 60 -74 years (n ¼ 242, mean age 69 + 4 years) and ≥75 years (n ¼ 380, mean age 82 + 4 years). Some exclusion criteria applied, 4 but on average, the patients were similar to those included in large registries. 9, 10 The ethics committee of each centre approved the study and each patient gave written informed consent for participation. Baseline assessment included medical history, signs, and symptoms of CHF, QoL, and end-of-life preference questionnaires, laboratory results, and the 6 min walk test.
Quality of life was measured by structured, self-administered questionnaires [Minnesota Living with CHF (MLwHF), 11 Duke Activity Status Index (DASI), 12 and short form of the IQOLA SF-36
]. Furthermore, Geriatric Depression Scale short form (GDS) 14 and the Hodkinson abbreviated mental test 15 were used.
Outcomes
End-of-life preferences were assessed by using a time trade-off (TTO) tool 6 and one question concerning CPR preference (yes, no, undecided). Both instruments were administered verbally after a descriptive introduction. Cardiopulmonary resuscitation preference was asked after explaining meaning and circumstances of CPR. To assess TTO, patients were asked whether they preferred living 2 years in their current state of health or living 1 year in excellent health. If 1 year in excellent health was chosen, the patients were asked whether they would prefer 2 years in their current state of health or 6 months in perfect health. If 2 years in the current state were chosen, then they were asked whether they would prefer 2 years in their current state of health or 18 months in perfect health. The series was continued until the point at which the choices were equivalent. This time point subtracted from 24 months yielded the number of months of survival time that the patient would be willing to trade. 6 End-of-life preferences were assessed at baseline, and at 12 and 18 months. In addition, CPR order during last hospitalization was assessed in patients who were included presently after discharge.
Statistical analysis
Results are shown as mean (SD), median (IQR), and numbers and percentages as appropriate. Patients were divided into four groups: not willing to trade any survival time, willing to trade ≤6 months, .6 -12 months, and .12 months. Group comparisons were done using independent t-test, Mann-Whitney U-test, or Fisher's exact test, as appropriate. Multivariable analysis was done using logistic regression with stepwise backward procedure (inclusion P ≤ 0.05, exclusion P . 0.1), including variables shown in Table 1 . No imputation for missing data was performed. Changes over time were assessed by using Wilcoxon signed ranks and Friedman's ANOVA, as appropriate, using Bonferroni adjustment where required. Adjusting results for participating centres did not significantly influence results. Therefore, unadjusted analyses are presented. A two-sided P-value of 0.05 or less was considered to be statistically significant. Calculations were done using the commercially available statistical package SPSS 15.0.
Results
Baseline characteristics are shown in 
Willingness to trade survival time
At baseline, 74% of the patients were not willing to trade any survival time for excellent health ( Figure 1A) . Of the remaining patients, approximately equal groups were willing to trade up to 6 months, .6 months to 1 year, or more than 1 year. Patients aged ≥75 years were slightly more likely to be willing to trade than younger patients (29 vs. 20%, P ¼ 0.01), whereas the proportion not responding to this question did not differ between the age groups (11% in both). During follow-up, the proportion of patients willing to trade any survival time decreased (Month 12: n ¼ 62 of 401, Month 18: n ¼ 48 of 368, Figure 2 , P , 0.01), with no differences between age groups. When considering all patients not responding to the question at Month 12 or withdrawing consent prior to this visit as End-of-life preferences of elderly patients with CHF willing to trade any survival time, the proportion of those not willing to trade would still be 72% (at Month 18, 75%).
Of the original 622 patients, 376 (60%) replied to the TTO question both at baseline and at Month 12 [117 (19%) died, 52 (8%) withdrew consent, 77 (12%) replied at only one time point]. Of these, the response was the same at both visits in 280 (75%) patients, with 263 (94%) not willing to trade any survival time ( Table 2) . A comparable picture was seen comparing the 339 patients who responded at both Months 12 and 18: no change in 280 (83%) patients, 22 (6%) patients with more, and 37 (11%) patients with less willingness to trade survival time, but the changes over time were no longer statistically significant (P ¼ 0.18). Surviving patients replying only once to the question did not differ significantly from the others (data not shown).
Predictors of willingness to trade
Patients indicating any willingness to trade survival time for symptom-free living differed in many ways from those unwilling to trade. They were older, more often female, lived more often on their own and/or were not married, had more signs and symptoms of CHF and poorer QoL. A history of selected comorbidities was also related to willingness to trade ( Table 3) . 0 -3, 1.01-1.52) . The c-statistic of this multivariable logistic regression model was 0.710 (95% CI 0.657-0.763). The best cut-off was a probability of 33%, separating patients into those with a high (n ¼ 117) and a low (n ¼ 404) likelihood to accept a shorter survival time. However, even in the 'high likelihood' group, more than half of the patients (52%) preferred longevity vs. 83% in the low likelihood group (P , 0.001). 
Resuscitation preferences
Most patients (n ¼ 603, 97%) responded to the resuscitation question. At baseline, approximately one-third did not want CPR ( Figure 1B) . Age-influenced preference for CPR to a limited extent only ( Figure 1B , P , 0.001).
The proportion not wanting resuscitation increased slightly over time ( Figure 2 , change over time P ¼ 0.01). Figure 3 depicts 
Resuscitation preferences in relation to resuscitation orders
A total of 481 patients (77%) were included in the study presently after discharge from hospital. Of these, both CPR preferences at study entry and CPR orders from pre-randomization hospitalization were known for 430 patients (89%). For 390 patients with distinct CPR preferences, patient preferences (as answered to the study question) differed from the hospital records 32% of the time (n ¼ 126; Figure 4) . No predictors for disagreement could be identified (data not shown).
Relation of willingness to trade and wishing cardiopulmonary resuscitation with mortality
During follow-up, 20% of the patients died ( Table 4) . There were no significant differences in either all-cause mortality or cardiovascular mortality in relation to patients' willingness to trade survival time or wish to be resuscitated if necessary. However, noncardiovascular deaths were more common in patients willing to trade survival time, with a similar trend in patients not wanting resuscitation ( Table 4) . No significant interaction with age or age group (, or ≥75 years) was seen. 16 This study addresses communication issues and describes important new findings regarding end-of-life preferences of elderly CHF patients with both reduced and preserved LVEF, exploring the willingness to trade survival time and resuscitation preferences and changes over 18 months. It also correlated resuscitation preferences with resuscitation orders. Most patients showed a high willingness to answer these difficult questions, confirming previous findings. 6, 17, 18 Importantly, the majority preferred longevity over QoL, and half wished to be resuscitated if necessary. This was also true in very old patients, although the rates of willingness to trade in favour of longevity, and to be resuscitated, decreased with age. To some extent, the findings of this study are in contrast to the general belief 19 and some previous findings 5, 20 that QoL is more important than longevity for elderly CHF patients, but confirm recently published results in younger patients. 6 Previous studies on health values have focused on seriously ill patients, 21 who often had cancer, 22 were hospitalized, 23 or were living in a nursing home. 24 In patients with CHF, the focus was either on end-stage disease (e.g. patients confronted with cardiac transplantation 5 ), younger patients, 6, 20, 23 or patients with various chronic diseases. 25 The vast majority of CHF patients, who are elderly, however, have received little attention. These previous studies found that health preferences may vary widely and may change over time not only in relation to changes in health status. The acceptability of a therapy which may result in reduced health seems to increase with time and this increase seems more likely in patients with a declining health status. 25 This response shift in relation to the disease trajectory inherent to the process of accommodating an illness has been subject to specific studies 26 and seems particularly relevant to life-threatening diseases. However, many of the previous studies 25 focused on the acceptability of burdensome treatment rather than the preference of longevity over QoL. With the availability of treatment to (solely) improve prognosis, as in CHF, the latter question may be more relevant. In fact, in the few patients having an ICD in our study, preferences were more in favour of longevity. One possible explanation for the low willingness to trade survival time for better health may be that CHF patients tend to overestimate their life expectancy, 27 which may result in favouring more aggressive therapy. 28 However, this applies to younger patients, whereas patients with advanced age usually underestimate their life expectancy. 27 Given the high proportion of elderly patients preferring longevity, it is unlikely that overestimating life expectancy is the main explanation for our findings. In agreement with previous results, 6,29 the majority neither changed their willingness to trade survival time nor their preference regarding CPR over time. Still, there were patients who did change their preferences and these patients did not display characteristics that would help to identify them. Besides severity of CHF and related symptoms, age, female sex, exercise intolerance, depression, and co-morbidities were relevant predictors of end-of-life preferences. Patients with normal LVEF showed more willingness to trade survival time, but this was largely explained by age and sex. In addition, psychosocial factors were relevant predictors. Other predictors, such as orthostatic response or constipation, were less obvious, suggesting that individual perception may vary considerably. Moreover, combining these characteristics did not allow for a reliable prediction. The findings, therefore, emphasize the importance of asking and incorporating the individual patient's wishes into decision making, irrespective of age, and to periodically repeat these discussions. 16 The difficulty in communication is highlighted by the significant discordance between CPR orders and patients' wishes, reinforcing earlier findings that physicians' perceptions of patients' preferences are not always accurate. 29 Mismatches between preferences and treatment were shown, especially in the direction of patients receiving less aggressive care than they are willing to undergo 30 or very old CHF patients receiving more aggressive care than they desired. 31 Insufficient communication about death and prognosis may partly be due to physicians' self-perceived inability to predict mortality in advanced CHF, 18 or their concerns that such discussions will destroy hope. 17 This results in patients not receiving the treatment they prefer. Effective communication regarding end-of-life issues seems to rank among the most important topics in patients with advanced CHF, resulting in changes in preferences for life support. 32 Thus, expecting death in the near term should not detract from this discussion, but it should not be postponed until patients are end-stage as patients seem to prefer learning about their prognosis and its implications at a time of optimal cognitive function. 33 
Limitations
There are limitations to such an assessment, the most important being the hypothetical nature of the questions posed, which may be particularly difficult for very old patients to understand, a small proportion of which even having dementia, despite the fact that these questionnaires have been validated and used with success. 5, 6 Importantly, excluding patients having reduced mental abilities as assessed by the Hodkinson abbreviated mental test did not influence results (data not shown). The population included in the study was primarily from middle European backgrounds and cultural differences in patients' willingness to engage in discussion regarding end-of-life preferences were not examined, limiting generalizability to patients from other socio-cultural backgrounds. In addition, it is inherent to studies that the study sample is selected and might not represent all patients. In particular, the results may not apply to patients who are sicker when being asked about their preferences. Still, as characteristics of our study population were comparable to those of large cohort studies, 9,10 our study population seems to be representative of a broad range of CHF patients.
Conclusion
Patients with CHF are willing to address their end-of-life preferences, often value longevity even at older age, but individual preferences are impossible to predict and may change over time, reinforcing the value of listening to patients to provide relevant insight and individualize care. 34 Openness and communication about prognosis, trajectories, and realistic treatment possibilities engender hope and allow patients to plan for their future. 17 This applies to various decisions that confront CHF patients, but may be particularly important with respect to ICD implantation, turning off the device, and treatment with purely symptomatic medical therapy that may even reduce survival.
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